^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    glycosylated recombinant human interleukin-7 (CYT107)

    i
    Other names: CYT107, Glyco-r-hIL-7, rhIL-7, IL-7, glycosylated rhIL-7, second-generation CYT 99 007, r-hIL-7, CYT-107
    Associations

    News

    Trials
    Company:
    Revimmune
    Drug class:
    IL-7 agonist
    Related drugs:
    Associations

    News

    Trials
    1m
    IMPULSE-7: Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (clinicaltrials.gov)
    P2, N=8, Terminated, Revimmune | N=12 --> 8 | Trial completion date: Dec 2022 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Dec 2023; non convincing results
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Nontuberculous mycobacteria
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IL7 (Interleukin 7)
    |
    CD8 expression
    |
    glycosylated recombinant human interleukin-7 (CYT107)
    1m
    InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (clinicaltrials.gov)
    P2, N=10, Terminated, Revimmune | Active, not recruiting --> Terminated; POOR ACCRUAL
    Trial termination
    |
    glycosylated recombinant human interleukin-7 (CYT107)
    5ms
    A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma. (ASCO-GU 2024)
    This is the first randomized trial of atezo +/- IL-7 (CYT107) in mUC. During the trial, the FDA approval for atezo in mUC was withdrawn, which limited enrollment. However, our results show that the addition of CYT107 to atezo is safe/tolerable, with comparable toxicity profile and efficacy to monotherapy.
    Clinical • P2 data • Metastases
    |
    IL7 (Interleukin 7)
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    7ms
    Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Sep 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    10ms
    A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC) (ESMO 2023)
    During the trial, the FDA approval for atezo in mUC was withdrawn, which limited enrollment. However, our results show that the addition of CYT107 to atezo is safe/tolerable, although there was no improvement in clinical outcomes compared to atezo monotherapy.
    Clinical • P2 data • Metastases
    |
    IL7 (Interleukin 7)
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    over1year
    Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    over1year
    Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    over2years
    Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=54, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
    over2years
    IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). (PubMed, J Immunother Cancer)
    Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56 natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.
    Clinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    IFNG expression • IL2 expression
    |
    Provenge (sipuleucel-T) • glycosylated recombinant human interleukin-7 (CYT107)
    over3years
    Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=54, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)